Results of a randomized, placebo-controlled, double-blind, 12-week, multicenter study of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with obstructive sleep apnea

Introduction: This phase 3 pivotal trial evaluated solriamfetol, a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects, for the treatment of excessive sleepiness (ES) in patients with  obstructive sleep apnea (OSA). ES is a common OSA symptom that can persist and affect activities of daily living despite primary treatment such as continuous positive airway pressure (CPAP) or oral appliances.
Source: Sleep Medicine - Category: Sleep Medicine Authors: Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research